SABR will be available as a treatment option through routine commissioning for patients (all ages) with controlled primary cancer presenting with up to three extracranial metachronous oligometastases which manifest after a disease-free interval following primary treatment of at least 6 months, in line with the criteria set out in this document.

NHS England will commission canakinumab for treating periodic fever syndromes: TRAPS HIDS/MKD and FMF in accordance with the criteria outlined in this document.

NHS England will commission human coagulation factor X in hereditary factor X deficiency (all ages) in accordance with the criteria outlined in this document.

These material have been created for Local Maternity Systems (LMS), Systems Leaders, clinical leaders, Trusts, and multi-disciplinary maternity teams to support progress on the transformation journey, to raise awareness of the Better Births vision, why it is important, and practical action that can be taken to achieve this vision.

This guide aims to support pharmacists, clinicians and other NHS professionals with managing the supply of medicines to their patients and details the national, regional and local management and escalation processes and communication routes for medicines supply issues in order to consolidate existing practice across industry, government and the NHS.

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

This service specification covers the provision of spinal cord injury services for adults and children.

This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

NHS England will not routinely commission hyperbaric oxygen therapy for diabetic lower limb ulceration in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.